Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
To steadily realize the benefits of the structural reforms pursued to date, establish a stable, high-quality earnings base, and advance the growth strategy for customer-focused businesses. The company will balance investments for growth with shareholder returns while maintaining financial soundness.
Extraordinary losses included impairment losses of ¥88,940 million, comprising ¥50,354 million for the Twaron business, ¥8,156 million for the carbon fiber business, and ¥25,400 million for the marketing rights for a type 2 diabetes treatment and fixed assets related to the pharmaceuticals business. The company also recorded ¥4,008 million in special retirement payments associated with its business restructuring.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥850,000 million |
| Operating profit | Not disclosed → ¥70,000 million |
| Profit attributable to owners of the parent | Not disclosed → ¥45,000 million |
| Net income per share | Not disclosed → 233.26 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2026: revenue of ¥873,190 million, business profit of ¥25,781 million, operating loss of ¥70,714 million, loss attributable to owners of the parent of ¥88,003 million, and basic loss per share of ¥456.33. |
| Reason for the revision | To steadily realize the benefits of the structural reforms pursued to date, establish a stable, high-quality earnings base, and advance the growth strategy for customer-focused businesses. The company will balance investments for growth with shareholder returns while maintaining financial soundness. |
| Details and amount of extraordinary loss | Extraordinary losses included impairment losses of ¥88,940 million, comprising ¥50,354 million for the Twaron business, ¥8,156 million for the carbon fiber business, and ¥25,400 million for the marketing rights for a type 2 diabetes treatment and fixed assets related to the pharmaceuticals business. The company also recorded ¥4,008 million in special retirement payments associated with its business restructuring. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To realize the benefits of the structural reforms pursued to date, establish a stable earnings base, and drive growth in customer-focused businesses centered on Apparel & Industries and Healthcare & Life Solutions. The company also stated that it will balance growth investments with shareholder returns while maintaining financial soundness.